中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
DRAK2 aggravates nonalcoholic fatty liver disease progression through SRSF6-associated RNA alternative splicing

文献类型：期刊论文

作者Li, Yufeng1,2; Xu, Junyu1; Lu, Yuting1; Bian, Hua4,5; Yang, Lin1,2; Wu, Honghong1,2; Zhang, Xinwen1; Zhang, Beilei1; Xiong, Maoqian6; Chang, Yafei7
刊名CELL METABOLISM
出版日期2021-10-05
卷号33期号:10页码:2004-+
ISSN号1550-4131
DOI10.1016/j.cmet.2021.09.008
通讯作者Xia, Mingfeng(dr_xiamingfeng@163.com) ; Tan, Minjia(mjtan@simm.ac.cn) ; Li, Jingya(jyli@simm.ac.cn)
英文摘要Nonalcoholic steatohepatitis (NASH) is an advanced stage of nonalcoholic fatty liver disease (NAFLD) with serious consequences that currently lacks approved pharmacological therapies. Recent studies suggest the close relationship between the pathogenesis of NAFLD and the dysregulation of RNA splicing machinery. Here, we reveal death-associated protein kinase-related apoptosis-inducing kinase-2 (DRAK2) is markedly upregulated in the livers of both NAFLD/NASH patients and NAFLD/NASH diet-fed mice. Hepatic deletion of DRAK2 suppresses the progression of hepatic steatosis to NASH. Comprehensive analyses of the phosphoproteome and transcriptome indicated a crucial role of DRAK2 in RNA splicing and identified the splicing factor SRSF6 as a direct binding protein of DRAK2. Further studies demonstrated that binding to DRAK2 inhibits SRSF6 phosphorylation by the SRSF kinase SRPK1 and regulates alternative splicing of mitochondrial function-related genes. In conclusion, our findings reveal an indispensable role of DRAK2 in NAFLD/NASH and offer a potential therapeutic target for this disease.
WOS关键词PROTEIN-KINASE ; SYSTEM ; NASH ; STEATOHEPATITIS ; MECHANISMS ; INHIBITORS ; DISCOVERY ; APOPTOSIS ; OBESITY ; ROBUST
资助项目National Natural Science Foundation of China[92057116] ; National Natural Science Foundation of China[81673493] ; National Natural Science Foundation of China[91753203] ; National Natural Science Foundation of China[32071432] ; National Natural Science Foundation of China[81821005] ; National Science and Technology Major Project[2018ZX09711002-004/018] ; National Key R&D Program of China[2020YFE0202200] ; Shanghai Natural Science Foundation[20ZR1410200]
WOS研究方向Cell Biology ; Endocrinology & Metabolism
语种英语
出版者CELL PRESS
WOS记录号WOS:000729469700013
源URL[http://119.78.100.183/handle/2S10ELR8/299178]  
专题新药研究国家重点实验室
通讯作者Xia, Mingfeng; Tan, Minjia; Li, Jingya
作者单位1.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
2.Univ Chinese Acad Sci, Beijing 100049, Peoples R China
3.Univ Chinese Acad Sci, Sch Pharmaceut Sci & Technol, Hangzhou Inst Adv Study, Hangzhou 310024, Peoples R China
4.Fudan Univ, Zhongshan Hosp, Dept Endocrinol & Metab, Shanghai 200032, Peoples R China
5.Fudan Inst Metab Dis, Shanghai 200032, Peoples R China
6.East China Normal Univ, Shanghai Engn Res Ctr Mol Therapeut & New Drug De, Sch Chem & Mol Engn, Shanghai 200062, Peoples R China
7.Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Dept Bioinformat & Biostat, Shanghai 200240, Peoples R China
推荐引用方式
GB/T 7714		 Li, Yufeng,Xu, Junyu,Lu, Yuting,et al. DRAK2 aggravates nonalcoholic fatty liver disease progression through SRSF6-associated RNA alternative splicing[J]. CELL METABOLISM,2021,33(10):2004-+.
APA Li, Yufeng.,Xu, Junyu.,Lu, Yuting.,Bian, Hua.,Yang, Lin.,...&Li, Jingya.(2021).DRAK2 aggravates nonalcoholic fatty liver disease progression through SRSF6-associated RNA alternative splicing.CELL METABOLISM,33(10),2004-+.
MLA Li, Yufeng,et al."DRAK2 aggravates nonalcoholic fatty liver disease progression through SRSF6-associated RNA alternative splicing".CELL METABOLISM 33.10(2021):2004-+.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。